Menu
Business Resources>Labs/Testing

ChromaDex Announces Top Line Results of its Second Human Clinical Trial

<p>ChromaDex Corp. (NASDAQ:CDXC announced today that the initial results of its second human clinical study of NIAGEN<sup>&reg;</sup> nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over 8-weeks.</p>
TAGS: Healthy Living Ingredients Business Resources
Hide comments

More information about text formats

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish
Related
A certificate of analysis does not equal transparency
A certificate of analysis does not equal transparency
Nov 15, 2018
FDA slide 9
FDA still finding same cGMP deficiencies at dietary supplement facilities
Nov 01, 2018
Selecting the right contract lab
SupplySide West podcast: Selecting the right contract lab
Oct 29, 2018
Botanical testing considerations
SupplySide West podcast: Botanical testing considerations
Oct 26, 2018